Founded in 2021, Laibo Ruichen is committed to the independent research and development and industrialization promotion of "First-in-Class" innovative drugs for bone and joint, and provides innovative treatment programs for the majority of bone and joint patients based on the unmet clinical drug demand in China and the world.

The original project team is from UC Davis Bone and Joint Regenerative Medicine Research Center; R&D has been carried out for more than 12 years, and the accumulated investment exceeds 30 million US dollars; Global originality, leading technology and high barriers can fill the gap in the market; The intellectual property rights are clear and authorized, and the research and development achievements have been published in many top scientific magazines in the world.

Founded in 2005, Nuovo Technology is a mature integrated Internet application service provider and a national certified dual soft and high-tech enterprise.

RAB001 is currently promoting clinical phase II, striving to achieve the world's first innovative drug (first-in-class) for the treatment of osteonecrosis in China, and to promote the new drug to developed regions such as the United States and Europe for global marketing and sales through commercial cooperation.